VEGFA and Genetic thrombotic microangiopathy: There is increasing evidence showing that anti-VEGF treatment is associated with cases of accelerated hypertension, worsening proteinuria, glomerular disease, thrombotic microangiopathy, and possible renal function decline [8, 10].